pharmaceutical daily news

Eli Lilly and Incyte Corporation scored a recommended approval of the 2-mg dose of a once-daily oral medication baricitinib from the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee, for the treatment of rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate.

Beximco Pharmaceuticals has begin the export Methocarbamol tablets to the US, generic equivalent to Auxilium Pharmaceuticals’ muscle relaxant Robaxin tablets, 500mg and 700mg. This product is a generic equivalent to Auxilium Pharmaceuticals’ muscle relaxant Robaxin tablets, which is for pain relief associated with acute musculoskeletal conditions. The first consignment was delivered

Hikma Pharmaceuticals has launched Dexrazoxane for Injection, 250mg and 500mg vials, the generic equivalent to Zinecard, through its US wholly-owned subsidiary West-Ward Pharmaceuticals Corp.

Boehringer Ingelheim and HealthPrize Technologies are expanding the RespiPoints digital support program to anyone taking one of several Boehringer Ingelheim medicines, including select medicines available in the Respimat inhaler. The RespiPoints program is a free web and mobile-based program that engages and rewards patients through education about their condition and

The U.S. Food and Drug Administration has approved Ultragenyx Pharmaceutical’s  Crysvita (burosumab), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).

Creso Pharma said Wednesday that CLV Frontier Brands Pty, its equal one-third joint venture with UK-based Baltic Beer Company and Canadian TSX Venture, is planning to have its first beers and tonics on sale in Europe and Canada during the summer, with the aim to later expand.

Sanofi has gotten an offer from Advent International, a global investor in healthcare sector, for purchase of Zentiva, Sanofi’s European generics business for €1,9 billion.

Herantis Pharma has gotten positive results from a safety evaluation in the ongoing Phase 1 clinical study of its investigational gene therapy product Lymfactin for the treatment of secondary lymphedema.